1814 related articles for article (PubMed ID: 33960219)
1. The Impact of Anticoagulation on COVID-19 (SARS CoV-2) Patient Outcomes: A Systematic Review.
Lazaridis D; Leung S; Kohler L; Smith CH; Kearson ML; Eraikhuemen N
J Pharm Pract; 2022 Dec; 35(6):1000-1006. PubMed ID: 33960219
[TBL] [Abstract][Full Text] [Related]
2. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection.
Obi AT; Barnes GD; Napolitano LM; Henke PK; Wakefield TW
J Vasc Surg Venous Lymphat Disord; 2021 Jan; 9(1):23-35. PubMed ID: 32916371
[TBL] [Abstract][Full Text] [Related]
3. Thromboelastography clot strength profiles and effect of systemic anticoagulation in COVID-19 acute respiratory distress syndrome: a prospective, observational study.
Bocci MG; Maviglia R; Consalvo LM; Grieco DL; Montini L; Mercurio G; Nardi G; Pisapia L; Cutuli SL; Biasucci DG; Gori C; Rosenkranz R; De Candia E; Carelli S; Natalini D; Antonelli M; Franceschi F
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12466-12479. PubMed ID: 33336766
[TBL] [Abstract][Full Text] [Related]
4. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
5. Coagulopathy of Coronavirus Disease 2019.
Iba T; Levy JH; Levi M; Connors JM; Thachil J
Crit Care Med; 2020 Sep; 48(9):1358-1364. PubMed ID: 32467443
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic anticoagulants for people hospitalised with COVID-19.
Flumignan RL; Tinôco JDS; Pascoal PI; Areias LL; Cossi MS; Fernandes MI; Costa IK; Souza L; Matar CF; Tendal B; Trevisani VF; Atallah ÁN; Nakano LC
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013739. PubMed ID: 33502773
[TBL] [Abstract][Full Text] [Related]
7. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.
Dobesh PP; Trujillo TC
Pharmacotherapy; 2020 Nov; 40(11):1130-1151. PubMed ID: 33006163
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 and its implications for thrombosis and anticoagulation.
Connors JM; Levy JH
Blood; 2020 Jun; 135(23):2033-2040. PubMed ID: 32339221
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Venous Thromboembolism in Critically Ill Coronavirus Disease 2019 Patients Receiving Prophylactic Anticoagulation.
Trigonis RA; Holt DB; Yuan R; Siddiqui AA; Craft MK; Khan BA; Kapoor R; Rahman O
Crit Care Med; 2020 Sep; 48(9):e805-e808. PubMed ID: 32618699
[TBL] [Abstract][Full Text] [Related]
10. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review.
Eljilany I; Elzouki AN
Vasc Health Risk Manag; 2020; 16():455-462. PubMed ID: 33223833
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic Complications of COVID-19 Infection: A Review.
Castro RA; Frishman WH
Cardiol Rev; 2021; 29(1):43-47. PubMed ID: 32947478
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients.
Moreno G; Carbonell R; Bodí M; Rodríguez A
Med Intensiva (Engl Ed); 2021; 45(1):42-55. PubMed ID: 32646669
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Kreidieh F; Temraz S
Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
[TBL] [Abstract][Full Text] [Related]
16. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
Helms J; Tacquard C; Severac F; Leonard-Lorant I; Ohana M; Delabranche X; Merdji H; Clere-Jehl R; Schenck M; Fagot Gandet F; Fafi-Kremer S; Castelain V; Schneider F; Grunebaum L; Anglés-Cano E; Sattler L; Mertes PM; Meziani F;
Intensive Care Med; 2020 Jun; 46(6):1089-1098. PubMed ID: 32367170
[TBL] [Abstract][Full Text] [Related]
17. The coagulopathy, endotheliopathy, and vasculitis of COVID-19.
Iba T; Connors JM; Levy JH
Inflamm Res; 2020 Dec; 69(12):1181-1189. PubMed ID: 32918567
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 coagulopathy - what should we treat?
Chowdary P
Exp Physiol; 2022 Jul; 107(7):749-758. PubMed ID: 35733235
[TBL] [Abstract][Full Text] [Related]
19. Complement activation and coagulopathy - an ominous duo in COVID19.
Tomo S; Kumar KP; Roy D; Sankanagoudar S; Purohit P; Yadav D; Banerjee M; Sharma P; Misra S
Expert Rev Hematol; 2021 Feb; 14(2):155-173. PubMed ID: 33480807
[TBL] [Abstract][Full Text] [Related]
20. Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study.
Akinosoglou K; Savopoulos C; Pouliakis A; Triantafyllidis C; Markatis E; Golemi F; Liontos A; Vadala C; Papanikolaou IC; Dimakopoulou V; Xarras P; Varela K; Kaiafa G; Mitsianis A; Chatzistamati A; Randou E; Savvanis S; Pavlaki M; Efraimidis G; Samaras V; Papazoglou D; Konstantinidou A; Panagopoulos P; Milionis H; On Behalf Of The Interact Study Group
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
